Core Viewpoint - Aveanna Healthcare Holdings Inc. has completed the acquisition of Thrive Skilled Pediatric Care, enhancing its position in the pediatric home care market and expanding its service offerings into new states [1][2][3]. Company Overview - Aveanna Healthcare is a diversified home care platform providing services to medically complex, high-cost patient populations, with a presence in 36 states [7]. - The company offers a wide range of healthcare services, including nursing, rehabilitation, therapy, and case management, aimed at providing high-quality, lower-cost alternatives to prolonged hospitalization [7]. Acquisition Details - Thrive SPC is one of the largest independent providers of pediatric home care, operating 23 locations across seven states [2]. - The acquisition is expected to create significant growth opportunities for Aveanna, reinforcing its commitment to clinical excellence and compassionate care [3]. - The deal was financed through a combination of common stock and cash [3]. Strategic Implications - The integration of Thrive SPC is anticipated to enhance Aveanna's existing footprint and introduce its specialized care model into two new states [2][3]. - The acquisition aligns with Aveanna's strategic mission to lead in delivering high-quality care while providing value and clinical innovation to payors and stakeholders [3]. Advisory and Legal Support - Edge Healthcare Partners acted as the financial advisor for Aveanna, while Cantor Fitzgerald & Co. served as the financial advisor for Thrive SPC [4]. - Legal counsel for Aveanna was provided by Bass, Berry & Sims, and Ropes & Gray LLP represented Thrive SPC [4].

Core Insights - Aveanna Healthcare Holdings Inc. reported strong financial results for Q1 2025, with revenue growth of 14.0% and adjusted EBITDA growth of 93.1% compared to the same period last year [2][8][10] - The company is optimistic about its strategic transformation and has raised its full-year 2025 revenue guidance to over $2.15 billion and adjusted EBITDA guidance to over $207 million [10][11] Financial Performance - Revenue for the three-month period ended March 29, 2025, was $559.2 million, up from $490.7 million for the same period in 2024, representing an increase of $68.6 million [3][30] - Gross margin increased to $183.6 million, or 32.8% of revenue, compared to $145.9 million, or 29.7% of revenue, for the prior year, marking a 25.9% increase [4][30] - Net income for the quarter was $5.2 million, a significant turnaround from a net loss of $11.2 million in the same quarter of 2024 [5][31] - Adjusted EBITDA reached $67.4 million, or 12.0% of revenue, compared to $34.9 million, or 7.1% of revenue, for the same period last year, reflecting a 93.1% increase [6][30] Segment Performance - The PDS segment saw a revenue increase of $65.0 million, while the HHH and MS segments contributed $2.1 million and $1.5 million increases, respectively [3][30] - The Field contribution margin improved to 16.5% from 11.8% year-over-year, indicating enhanced operational efficiency [30][34] Cash Flow and Liquidity - As of March 29, 2025, the company had cash of $71.5 million and an incremental borrowing capacity of $56.2 million under its securitization facility [9][29] - Free cash flow for the quarter was $(12.9) million, reflecting cash used in operating activities of $(8.6) million [9][24] Strategic Outlook - The company emphasizes the importance of government and payor partnerships in driving core volume growth and clinical outcomes [2][10] - Aveanna's management is confident in the company's trajectory, citing strategic cost reductions and improved reimbursement rates as key drivers of performance [10][11]